Skip to content

A COMPARITIVE STUDY OF TWO DIFFERENT O.1 % VITAMIN B12 DYE FOR STRENGTHENING OF CORNEA IN THIN AND CONICAL CORNEAS

A prospective clinical Study to evaluate the Safety and Efficacy of two different 0.1% Riboflavin used in Corneal Cross-linking treatment for patients with Keratoconus

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/11/021841
Enrollment
100
Registered
2019-11-01
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- keratoconus Health Condition 2: H186- Keratoconus

Interventions

Intervention1: 0.1% Riboflavin (Flavin solution): 0.1% Flavin dye will be used for conventional cross linking and the safety and efficacy will be compared with the 0.1% riboflavin formulation from an

Sponsors

BIOTECH HEALTHCARE PVT LTD
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Unilateral/bilateral 2. A diagnosis of keratoconus. 3. Progressing keratoconus. 4. Patients with Keratometric readings 5. Patients >= 18 years of age 6. Patients with clear central cornea, without apical scarring. 7. Patients with corneal thickness >= 400 microns at the thinnest point. 8. Patient willing to participate and sign informed consent 9. Patient willing to come for all post-operative follow-up procedures as defined in study protocol.

Exclusion criteria

Exclusion criteria: 1. Eyes classified as either normal, atypical normal (except corneal ectasia), or keratoconus suspect on the severity grading scheme. 2. A history of previous corneal surgery or the insertion of intrastromal ring implantation in the eye(s) to be treated. 3. Previous corneal or Intraocular surgery 4. Pellucid marginal corneal degeneration 5. Eyes which are aphakic or pseudophakic and do not have a UV blocking lens implanted. 6. A history of delayed epithelial healing. 7. Patients with nystagmus or any other condition that would have prevented a steady gaze during the CXL treatment or other diagnostic tests. 8. Pregnancy & Lactation 9. Concurrent participation in another drug or device Study.

Design outcomes

Primary

MeasureTime frame
â?¢Progression of Keratoconus [Time Frame: Pre-operative visit, 1,3, 6 & 12 Months Follow-up] â?¢Best Corrected Visual acuity [Time Frame: Pre-operative visit, 1,3, 6 & 12 Months Follow-up] Visual Acuity (VA) is measured in logMAR. LogMAR is the "logarithm of the minimum angle of resolution". A lower logMAR value indicates better visual acuity. â?¢Endothelial Cell Count [Time Frame: Pre-operative visit, 1,3, 6 & 12 Months Follow-up] As measured by Specular Microscope Timepoint: Pre-operative visit, 1,3, 6 & 12 Months Follow-up

Secondary

MeasureTime frame
Refraction Corneal Demarcation Line Depth (DLD) Corneal Haze Uncorrected Visual acuity Corneal Thickness Change in K1, K2 and Kmean Value Timepoint: Pre-operative visit, 1,3, 6 & 12 Months Follow-up

Countries

India

Contacts

Public Contactdr sri ganesh

nethradhama super speciality eye hospital

phacomaverick@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026